DeepLook, Inc.’s Segmentation and Measurement Tool Captures FDA Clearance
One-click tool is designed to deliver precision consistently across all imaging modalities.
Connecticut-based software firm DeepLook, Inc., announced Thursday it has received U.S. Food & Drug Administration approval for DL Precise, its one-click segmentation and measurement tool.
This tool is designed to automate segmentation and measurement of suspicious findings across all imaging modalities, potentially improving workflow and reporting precision. Still, company officials noted, users can maintain full control and modify any automated measurement if they choose.
At left, one-click segmentation and measurement rendered by DL Precise. At right, DL Precise uses vivid color to illustrate segmentation.
Credit: DeepLook
DL Precise uses deterministic algorithms to contour object margins and measure long and short dimension axes, area, and estimated volume. With its single-click activation, it side-steps the complex, time-consuming manual set-up that frequently comes with current semi-automatic segmentation tools.
Not only does DL Precise work with any DICOM image and on all 510(k)-cleared viewers, but its patented technology can also be used universally with mammography, ultrasound, CT, and MRI, and the data captured can be fed directly into structured reports, making image comparisons across modalities easier. It can also be adapted to each viewer interface for easy PACS integration, according to company data.
DeepLook also has plans for future decision-support and diagnostic products based on radiomic data.
Can Contrast-Enhanced Mammography be a Viable Screening Alternative to Breast MRI?
June 17th 2025While the addition of contrast-enhanced mammography (CEM) to digital breast tomosynthesis (DBT) led to over a 13 percent increase in false positive cases, researchers also noted over double the cancer yield per 1,000 women in comparison to DBT alone.
Ultrasound-Guided Thermal Ablation Shows Low Recurrence of Thyroid Carcinoma at Five Years
June 16th 2025In a meta-analysis involving over 2,200 patients with T1NoMo papillary thyroid carcinoma, researchers noted 2 percent recurrence and no cases of lymph node metastasis five years after ultrasound-guided thermal ablation.
Contrast-Enhanced Mammography and High-Concentration ICM Dosing: What a New Study Reveals
June 16th 2025New research showed a 96 to 97 percent sensitivity for contrast-enhanced mammography (CEM) with an increased iodine delivery rate facilitating robust contrast enhancement for women with aggressive breast cancer.
